The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antihypertensive Agents Market Research Report 2025
Synopsis
Highlights
The global Antihypertensive Agents market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Antihypertensive Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Antihypertensive Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The global market for Antihypertensive Agents in Children is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of Antihypertensive Agents include Baxter International, Pfizer, Sandoz, Teva Pharmaceuticals, Bayer, Johnson & Johnson, Sun Pharmaceutical Industries, Merck and AstraZeneca, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, Thiazide Diuretics, which accounted for % of the global market of Antihypertensive Agents in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antihypertensive Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihypertensive Agents.
The Antihypertensive Agents market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Antihypertensive Agents market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihypertensive Agents companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Baxter International
Pfizer
Sandoz
Teva Pharmaceuticals
Bayer
Johnson & Johnson
Sun Pharmaceutical Industries
Merck
AstraZeneca
Daiichi Sankyo
Takeda
Actelion
Viatris
United Therapeutics
Lupin Limited
Hikma Pharmaceuticals
Aurobindo Pharma
Camber Pharmaceutical
Major Pharmaceuticals
Glenmark Pharmaceuticals
Zydus Pharmaceuticals
Amneal Pharmaceuticals
Endo International
Unichem Laboratories
Huahai Pharmaceutical
Shijiazhuang Pharma Group
Shanghai Shyndec Pharmaceutical
Product Type Insights
Global markets are presented by Antihypertensive Agents type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Antihypertensive Agents are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Antihypertensive Agents segment by Type
Thiazide Diuretics
Calcium Channel Blockers (CCB)
ACE Inhibitors
Angiotensin II Receptor Antagonists (ARBs)
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Antihypertensive Agents market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Antihypertensive Agents market.
Antihypertensive Agents Segment by Application
Children
Adult
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Antihypertensive Agents market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihypertensive Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Antihypertensive Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Antihypertensive Agents industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihypertensive Agents.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antihypertensive Agents companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Highlights
The global Antihypertensive Agents market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Antihypertensive Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Antihypertensive Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The global market for Antihypertensive Agents in Children is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of Antihypertensive Agents include Baxter International, Pfizer, Sandoz, Teva Pharmaceuticals, Bayer, Johnson & Johnson, Sun Pharmaceutical Industries, Merck and AstraZeneca, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, Thiazide Diuretics, which accounted for % of the global market of Antihypertensive Agents in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antihypertensive Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihypertensive Agents.
The Antihypertensive Agents market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Antihypertensive Agents market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihypertensive Agents companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Baxter International
Pfizer
Sandoz
Teva Pharmaceuticals
Bayer
Johnson & Johnson
Sun Pharmaceutical Industries
Merck
AstraZeneca
Daiichi Sankyo
Takeda
Actelion
Viatris
United Therapeutics
Lupin Limited
Hikma Pharmaceuticals
Aurobindo Pharma
Camber Pharmaceutical
Major Pharmaceuticals
Glenmark Pharmaceuticals
Zydus Pharmaceuticals
Amneal Pharmaceuticals
Endo International
Unichem Laboratories
Huahai Pharmaceutical
Shijiazhuang Pharma Group
Shanghai Shyndec Pharmaceutical
Product Type Insights
Global markets are presented by Antihypertensive Agents type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Antihypertensive Agents are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Antihypertensive Agents segment by Type
Thiazide Diuretics
Calcium Channel Blockers (CCB)
ACE Inhibitors
Angiotensin II Receptor Antagonists (ARBs)
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Antihypertensive Agents market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Antihypertensive Agents market.
Antihypertensive Agents Segment by Application
Children
Adult
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Antihypertensive Agents market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihypertensive Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Antihypertensive Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Antihypertensive Agents industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihypertensive Agents.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antihypertensive Agents companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antihypertensive Agents Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Thiazide Diuretics
1.2.3 Calcium Channel Blockers (CCB)
1.2.4 ACE Inhibitors
1.2.5 Angiotensin II Receptor Antagonists (ARBs)
1.3 Market by Application
1.3.1 Global Antihypertensive Agents Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Children
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antihypertensive Agents Market Perspective (2017-2028)
2.2 Antihypertensive Agents Growth Trends by Region
2.2.1 Antihypertensive Agents Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antihypertensive Agents Historic Market Size by Region (2017-2022)
2.2.3 Antihypertensive Agents Forecasted Market Size by Region (2023-2028)
2.3 Antihypertensive Agents Market Dynamics
2.3.1 Antihypertensive Agents Industry Trends
2.3.2 Antihypertensive Agents Market Drivers
2.3.3 Antihypertensive Agents Market Challenges
2.3.4 Antihypertensive Agents Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antihypertensive Agents Players by Revenue
3.1.1 Global Top Antihypertensive Agents Players by Revenue (2017-2022)
3.1.2 Global Antihypertensive Agents Revenue Market Share by Players (2017-2022)
3.2 Global Antihypertensive Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antihypertensive Agents Revenue
3.4 Global Antihypertensive Agents Market Concentration Ratio
3.4.1 Global Antihypertensive Agents Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antihypertensive Agents Revenue in 2021
3.5 Antihypertensive Agents Key Players Head office and Area Served
3.6 Key Players Antihypertensive Agents Product Solution and Service
3.7 Date of Enter into Antihypertensive Agents Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antihypertensive Agents Breakdown Data by Type
4.1 Global Antihypertensive Agents Historic Market Size by Type (2017-2022)
4.2 Global Antihypertensive Agents Forecasted Market Size by Type (2023-2028)
5 Antihypertensive Agents Breakdown Data by Application
5.1 Global Antihypertensive Agents Historic Market Size by Application (2017-2022)
5.2 Global Antihypertensive Agents Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antihypertensive Agents Market Size (2017-2028)
6.2 North America Antihypertensive Agents Market Size by Country (2017-2022)
6.3 North America Antihypertensive Agents Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Antihypertensive Agents Market Size (2017-2028)
7.2 Europe Antihypertensive Agents Market Size by Country (2017-2022)
7.3 Europe Antihypertensive Agents Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antihypertensive Agents Market Size (2017-2028)
8.2 Asia-Pacific Antihypertensive Agents Market Size by Country (2017-2022)
8.3 Asia-Pacific Antihypertensive Agents Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Antihypertensive Agents Market Size (2017-2028)
9.2 Latin America Antihypertensive Agents Market Size by Country (2017-2022)
9.3 Latin America Antihypertensive Agents Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antihypertensive Agents Market Size (2017-2028)
10.2 Middle East & Africa Antihypertensive Agents Market Size by Country (2017-2022)
10.3 Middle East & Africa Antihypertensive Agents Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Baxter International
11.1.1 Baxter International Company Detail
11.1.2 Baxter International Business Overview
11.1.3 Baxter International Antihypertensive Agents Introduction
11.1.4 Baxter International Revenue in Antihypertensive Agents Business (2017-2022)
11.1.5 Baxter International Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Antihypertensive Agents Introduction
11.2.4 Pfizer Revenue in Antihypertensive Agents Business (2017-2022)
11.2.5 Pfizer Recent Development
11.3 Sandoz
11.3.1 Sandoz Company Detail
11.3.2 Sandoz Business Overview
11.3.3 Sandoz Antihypertensive Agents Introduction
11.3.4 Sandoz Revenue in Antihypertensive Agents Business (2017-2022)
11.3.5 Sandoz Recent Development
11.4 Teva Pharmaceuticals
11.4.1 Teva Pharmaceuticals Company Detail
11.4.2 Teva Pharmaceuticals Business Overview
11.4.3 Teva Pharmaceuticals Antihypertensive Agents Introduction
11.4.4 Teva Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.4.5 Teva Pharmaceuticals Recent Development
11.5 Bayer
11.5.1 Bayer Company Detail
11.5.2 Bayer Business Overview
11.5.3 Bayer Antihypertensive Agents Introduction
11.5.4 Bayer Revenue in Antihypertensive Agents Business (2017-2022)
11.5.5 Bayer Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Antihypertensive Agents Introduction
11.6.4 Johnson & Johnson Revenue in Antihypertensive Agents Business (2017-2022)
11.6.5 Johnson & Johnson Recent Development
11.7 Sun Pharmaceutical Industries
11.7.1 Sun Pharmaceutical Industries Company Detail
11.7.2 Sun Pharmaceutical Industries Business Overview
11.7.3 Sun Pharmaceutical Industries Antihypertensive Agents Introduction
11.7.4 Sun Pharmaceutical Industries Revenue in Antihypertensive Agents Business (2017-2022)
11.7.5 Sun Pharmaceutical Industries Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Antihypertensive Agents Introduction
11.8.4 Merck Revenue in Antihypertensive Agents Business (2017-2022)
11.8.5 Merck Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Detail
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Antihypertensive Agents Introduction
11.9.4 AstraZeneca Revenue in Antihypertensive Agents Business (2017-2022)
11.9.5 AstraZeneca Recent Development
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Company Detail
11.10.2 Daiichi Sankyo Business Overview
11.10.3 Daiichi Sankyo Antihypertensive Agents Introduction
11.10.4 Daiichi Sankyo Revenue in Antihypertensive Agents Business (2017-2022)
11.10.5 Daiichi Sankyo Recent Development
11.11 Takeda
11.11.1 Takeda Company Detail
11.11.2 Takeda Business Overview
11.11.3 Takeda Antihypertensive Agents Introduction
11.11.4 Takeda Revenue in Antihypertensive Agents Business (2017-2022)
11.11.5 Takeda Recent Development
11.12 Actelion
11.12.1 Actelion Company Detail
11.12.2 Actelion Business Overview
11.12.3 Actelion Antihypertensive Agents Introduction
11.12.4 Actelion Revenue in Antihypertensive Agents Business (2017-2022)
11.12.5 Actelion Recent Development
11.13 Viatris
11.13.1 Viatris Company Detail
11.13.2 Viatris Business Overview
11.13.3 Viatris Antihypertensive Agents Introduction
11.13.4 Viatris Revenue in Antihypertensive Agents Business (2017-2022)
11.13.5 Viatris Recent Development
11.14 United Therapeutics
11.14.1 United Therapeutics Company Detail
11.14.2 United Therapeutics Business Overview
11.14.3 United Therapeutics Antihypertensive Agents Introduction
11.14.4 United Therapeutics Revenue in Antihypertensive Agents Business (2017-2022)
11.14.5 United Therapeutics Recent Development
11.15 Lupin Limited
11.15.1 Lupin Limited Company Detail
11.15.2 Lupin Limited Business Overview
11.15.3 Lupin Limited Antihypertensive Agents Introduction
11.15.4 Lupin Limited Revenue in Antihypertensive Agents Business (2017-2022)
11.15.5 Lupin Limited Recent Development
11.16 Hikma Pharmaceuticals
11.16.1 Hikma Pharmaceuticals Company Detail
11.16.2 Hikma Pharmaceuticals Business Overview
11.16.3 Hikma Pharmaceuticals Antihypertensive Agents Introduction
11.16.4 Hikma Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.16.5 Hikma Pharmaceuticals Recent Development
11.17 Aurobindo Pharma
11.17.1 Aurobindo Pharma Company Detail
11.17.2 Aurobindo Pharma Business Overview
11.17.3 Aurobindo Pharma Antihypertensive Agents Introduction
11.17.4 Aurobindo Pharma Revenue in Antihypertensive Agents Business (2017-2022)
11.17.5 Aurobindo Pharma Recent Development
11.18 Camber Pharmaceutical
11.18.1 Camber Pharmaceutical Company Detail
11.18.2 Camber Pharmaceutical Business Overview
11.18.3 Camber Pharmaceutical Antihypertensive Agents Introduction
11.18.4 Camber Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022)
11.18.5 Camber Pharmaceutical Recent Development
11.19 Major Pharmaceuticals
11.19.1 Major Pharmaceuticals Company Detail
11.19.2 Major Pharmaceuticals Business Overview
11.19.3 Major Pharmaceuticals Antihypertensive Agents Introduction
11.19.4 Major Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.19.5 Major Pharmaceuticals Recent Development
11.20 Glenmark Pharmaceuticals
11.20.1 Glenmark Pharmaceuticals Company Detail
11.20.2 Glenmark Pharmaceuticals Business Overview
11.20.3 Glenmark Pharmaceuticals Antihypertensive Agents Introduction
11.20.4 Glenmark Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.20.5 Glenmark Pharmaceuticals Recent Development
11.21 Zydus Pharmaceuticals
11.21.1 Zydus Pharmaceuticals Company Detail
11.21.2 Zydus Pharmaceuticals Business Overview
11.21.3 Zydus Pharmaceuticals Antihypertensive Agents Introduction
11.21.4 Zydus Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.21.5 Zydus Pharmaceuticals Recent Development
11.22 Amneal Pharmaceuticals
11.22.1 Amneal Pharmaceuticals Company Detail
11.22.2 Amneal Pharmaceuticals Business Overview
11.22.3 Amneal Pharmaceuticals Antihypertensive Agents Introduction
11.22.4 Amneal Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.22.5 Amneal Pharmaceuticals Recent Development
11.23 Endo International
11.23.1 Endo International Company Detail
11.23.2 Endo International Business Overview
11.23.3 Endo International Antihypertensive Agents Introduction
11.23.4 Endo International Revenue in Antihypertensive Agents Business (2017-2022)
11.23.5 Endo International Recent Development
11.24 Unichem Laboratories
11.24.1 Unichem Laboratories Company Detail
11.24.2 Unichem Laboratories Business Overview
11.24.3 Unichem Laboratories Antihypertensive Agents Introduction
11.24.4 Unichem Laboratories Revenue in Antihypertensive Agents Business (2017-2022)
11.24.5 Unichem Laboratories Recent Development
11.25 Huahai Pharmaceutical
11.25.1 Huahai Pharmaceutical Company Detail
11.25.2 Huahai Pharmaceutical Business Overview
11.25.3 Huahai Pharmaceutical Antihypertensive Agents Introduction
11.25.4 Huahai Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022)
11.25.5 Huahai Pharmaceutical Recent Development
11.26 Shijiazhuang Pharma Group
11.26.1 Shijiazhuang Pharma Group Company Detail
11.26.2 Shijiazhuang Pharma Group Business Overview
11.26.3 Shijiazhuang Pharma Group Antihypertensive Agents Introduction
11.26.4 Shijiazhuang Pharma Group Revenue in Antihypertensive Agents Business (2017-2022)
11.26.5 Shijiazhuang Pharma Group Recent Development
11.27 Shanghai Shyndec Pharmaceutical
11.27.1 Shanghai Shyndec Pharmaceutical Company Detail
11.27.2 Shanghai Shyndec Pharmaceutical Business Overview
11.27.3 Shanghai Shyndec Pharmaceutical Antihypertensive Agents Introduction
11.27.4 Shanghai Shyndec Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022)
11.27.5 Shanghai Shyndec Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Antihypertensive Agents Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Thiazide Diuretics
Table 3. Key Players of Calcium Channel Blockers (CCB)
Table 4. Key Players of ACE Inhibitors
Table 5. Key Players of Angiotensin II Receptor Antagonists (ARBs)
Table 6. Global Antihypertensive Agents Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Antihypertensive Agents Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Antihypertensive Agents Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Antihypertensive Agents Market Share by Region (2017-2022)
Table 10. Global Antihypertensive Agents Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Antihypertensive Agents Market Share by Region (2023-2028)
Table 12. Antihypertensive Agents Market Trends
Table 13. Antihypertensive Agents Market Drivers
Table 14. Antihypertensive Agents Market Challenges
Table 15. Antihypertensive Agents Market Restraints
Table 16. Global Antihypertensive Agents Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Antihypertensive Agents Market Share by Players (2017-2022)
Table 18. Global Top Antihypertensive Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihypertensive Agents as of 2021)
Table 19. Ranking of Global Top Antihypertensive Agents Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Antihypertensive Agents Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antihypertensive Agents Product Solution and Service
Table 23. Date of Enter into Antihypertensive Agents Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antihypertensive Agents Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Antihypertensive Agents Revenue Market Share by Type (2017-2022)
Table 27. Global Antihypertensive Agents Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Antihypertensive Agents Revenue Market Share by Type (2023-2028)
Table 29. Global Antihypertensive Agents Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Antihypertensive Agents Revenue Market Share by Application (2017-2022)
Table 31. Global Antihypertensive Agents Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Antihypertensive Agents Revenue Market Share by Application (2023-2028)
Table 33. North America Antihypertensive Agents Market Size by Country (2017-2022) & (US$ Million)
Table 34. North America Antihypertensive Agents Market Size by Country (2023-2028) & (US$ Million)
Table 35. Europe Antihypertensive Agents Market Size by Country (2017-2022) & (US$ Million)
Table 36. Europe Antihypertensive Agents Market Size by Country (2023-2028) & (US$ Million)
Table 37. Asia-Pacific Antihypertensive Agents Market Size by Region (2017-2022) & (US$ Million)
Table 38. Asia-Pacific Antihypertensive Agents Market Size by Region (2023-2028) & (US$ Million)
Table 39. Latin America Antihypertensive Agents Market Size by Country (2017-2022) & (US$ Million)
Table 40. Latin America Antihypertensive Agents Market Size by Country (2023-2028) & (US$ Million)
Table 41. Middle East & Africa Antihypertensive Agents Market Size by Country (2017-2022) & (US$ Million)
Table 42. Middle East & Africa Antihypertensive Agents Market Size by Country (2023-2028) & (US$ Million)
Table 43. Baxter International Company Detail
Table 44. Baxter International Business Overview
Table 45. Baxter International Antihypertensive Agents Product
Table 46. Baxter International Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 47. Baxter International Recent Development
Table 48. Pfizer Company Detail
Table 49. Pfizer Business Overview
Table 50. Pfizer Antihypertensive Agents Product
Table 51. Pfizer Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 52. Pfizer Recent Development
Table 53. Sandoz Company Detail
Table 54. Sandoz Business Overview
Table 55. Sandoz Antihypertensive Agents Product
Table 56. Sandoz Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 57. Sandoz Recent Development
Table 58. Teva Pharmaceuticals Company Detail
Table 59. Teva Pharmaceuticals Business Overview
Table 60. Teva Pharmaceuticals Antihypertensive Agents Product
Table 61. Teva Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 62. Teva Pharmaceuticals Recent Development
Table 63. Bayer Company Detail
Table 64. Bayer Business Overview
Table 65. Bayer Antihypertensive Agents Product
Table 66. Bayer Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 67. Bayer Recent Development
Table 68. Johnson & Johnson Company Detail
Table 69. Johnson & Johnson Business Overview
Table 70. Johnson & Johnson Antihypertensive Agents Product
Table 71. Johnson & Johnson Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 72. Johnson & Johnson Recent Development
Table 73. Sun Pharmaceutical Industries Company Detail
Table 74. Sun Pharmaceutical Industries Business Overview
Table 75. Sun Pharmaceutical Industries Antihypertensive Agents Product
Table 76. Sun Pharmaceutical Industries Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 77. Sun Pharmaceutical Industries Recent Development
Table 78. Merck Company Detail
Table 79. Merck Business Overview
Table 80. Merck Antihypertensive Agents Product
Table 81. Merck Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 82. Merck Recent Development
Table 83. AstraZeneca Company Detail
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Antihypertensive Agents Product
Table 86. AstraZeneca Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 87. AstraZeneca Recent Development
Table 88. Daiichi Sankyo Company Detail
Table 89. Daiichi Sankyo Business Overview
Table 90. Daiichi Sankyo Antihypertensive Agents Product
Table 91. Daiichi Sankyo Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 92. Daiichi Sankyo Recent Development
Table 93. Takeda Company Detail
Table 94. Takeda Business Overview
Table 95. Takeda Antihypertensive AgentsProduct
Table 96. Takeda Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 97. Takeda Recent Development
Table 98. Actelion Company Detail
Table 99. Actelion Business Overview
Table 100. Actelion Antihypertensive AgentsProduct
Table 101. Actelion Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 102. Actelion Recent Development
Table 103. Viatris Company Detail
Table 104. Viatris Business Overview
Table 105. Viatris Antihypertensive AgentsProduct
Table 106. Viatris Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 107. Viatris Recent Development
Table 108. United Therapeutics Company Detail
Table 109. United Therapeutics Business Overview
Table 110. United Therapeutics Antihypertensive AgentsProduct
Table 111. United Therapeutics Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 112. United Therapeutics Recent Development
Table 113. Lupin Limited Company Detail
Table 114. Lupin Limited Business Overview
Table 115. Lupin Limited Antihypertensive AgentsProduct
Table 116. Lupin Limited Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 117. Lupin Limited Recent Development
Table 118. Hikma Pharmaceuticals Company Detail
Table 119. Hikma Pharmaceuticals Business Overview
Table 120. Hikma Pharmaceuticals Antihypertensive AgentsProduct
Table 121. Hikma Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 122. Hikma Pharmaceuticals Recent Development
Table 123. Aurobindo Pharma Company Detail
Table 124. Aurobindo Pharma Business Overview
Table 125. Aurobindo Pharma Antihypertensive AgentsProduct
Table 126. Aurobindo Pharma Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 127. Aurobindo Pharma Recent Development
Table 128. Camber Pharmaceutical Company Detail
Table 129. Camber Pharmaceutical Business Overview
Table 130. Camber Pharmaceutical Antihypertensive AgentsProduct
Table 131. Camber Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 132. Camber Pharmaceutical Recent Development
Table 133. Major Pharmaceuticals Company Detail
Table 134. Major Pharmaceuticals Business Overview
Table 135. Major Pharmaceuticals Antihypertensive AgentsProduct
Table 136. Major Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 137. Major Pharmaceuticals Recent Development
Table 138. Glenmark Pharmaceuticals Company Detail
Table 139. Glenmark Pharmaceuticals Business Overview
Table 140. Glenmark Pharmaceuticals Antihypertensive AgentsProduct
Table 141. Glenmark Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 142. Glenmark Pharmaceuticals Recent Development
Table 143. Zydus Pharmaceuticals Company Detail
Table 144. Zydus Pharmaceuticals Business Overview
Table 145. Zydus Pharmaceuticals Antihypertensive AgentsProduct
Table 146. Zydus Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 147. Zydus Pharmaceuticals Recent Development
Table 148. Amneal Pharmaceuticals Company Detail
Table 149. Amneal Pharmaceuticals Business Overview
Table 150. Amneal Pharmaceuticals Antihypertensive AgentsProduct
Table 151. Amneal Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 152. Amneal Pharmaceuticals Recent Development
Table 153. Endo International Company Detail
Table 154. Endo International Business Overview
Table 155. Endo International Antihypertensive AgentsProduct
Table 156. Endo International Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 157. Endo International Recent Development
Table 158. Unichem Laboratories Company Detail
Table 159. Unichem Laboratories Business Overview
Table 160. Unichem Laboratories Antihypertensive AgentsProduct
Table 161. Unichem Laboratories Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 162. Unichem Laboratories Recent Development
Table 163. Huahai Pharmaceutical Company Detail
Table 164. Huahai Pharmaceutical Business Overview
Table 165. Huahai Pharmaceutical Antihypertensive AgentsProduct
Table 166. Huahai Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 167. Huahai Pharmaceutical Recent Development
Table 168. Shijiazhuang Pharma Group Company Detail
Table 169. Shijiazhuang Pharma Group Business Overview
Table 170. Shijiazhuang Pharma Group Antihypertensive AgentsProduct
Table 171. Shijiazhuang Pharma Group Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 172. Shijiazhuang Pharma Group Recent Development
Table 173. Shanghai Shyndec Pharmaceutical Company Detail
Table 174. Shanghai Shyndec Pharmaceutical Business Overview
Table 175. Shanghai Shyndec Pharmaceutical Antihypertensive AgentsProduct
Table 176. Shanghai Shyndec Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022) & (US$ Million)
Table 177. Shanghai Shyndec Pharmaceutical Recent Development
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antihypertensive Agents Market Share by Type: 2021 VS 2028
Figure 2. Thiazide Diuretics Features
Figure 3. Calcium Channel Blockers (CCB) Features
Figure 4. ACE Inhibitors Features
Figure 5. Angiotensin II Receptor Antagonists (ARBs) Features
Figure 6. Global Antihypertensive Agents Market Share by Application in 2021 & 2028
Figure 7. Children Case Studies
Figure 8. Adult Case Studies
Figure 9. Antihypertensive Agents Report Years Considered
Figure 10. Global Antihypertensive Agents Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Antihypertensive Agents Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Antihypertensive Agents Market Share by Region: 2021 VS 2028
Figure 13. Global Antihypertensive Agents Market Share by Players in 2021
Figure 14. Global Top Antihypertensive Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihypertensive Agents as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Antihypertensive Agents Revenue in 2021
Figure 16. North America Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Antihypertensive Agents Market Share by Country (2017-2028)
Figure 18. United States Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Antihypertensive Agents Market Share by Country (2017-2028)
Figure 22. Germany Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Antihypertensive Agents Market Share by Region (2017-2028)
Figure 30. China Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Antihypertensive Agents Market Share by Country (2017-2028)
Figure 38. Mexico Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Antihypertensive Agents Market Share by Country (2017-2028)
Figure 42. Turkey Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Antihypertensive Agents Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Baxter International Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 45. Pfizer Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 46. Sandoz Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 47. Teva Pharmaceuticals Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 48. Bayer Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 49. Johnson & Johnson Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 50. Sun Pharmaceutical Industries Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 51. Merck Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 52. AstraZeneca Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 53. Daiichi Sankyo Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 54. Takeda Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 55. Actelion Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 56. Viatris Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 57. United Therapeutics Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 58. Lupin Limited Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 59. Hikma Pharmaceuticals Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 60. Aurobindo Pharma Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 61. Camber Pharmaceutical Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 62. Major Pharmaceuticals Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 63. Glenmark Pharmaceuticals Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 64. Zydus Pharmaceuticals Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 65. Amneal Pharmaceuticals Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 66. Endo International Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 67. Unichem Laboratories Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 68. Huahai Pharmaceutical Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 69. Shijiazhuang Pharma Group Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 70. Shanghai Shyndec Pharmaceutical Revenue Growth Rate in Antihypertensive Agents Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
